Abbott Laboratories (ABT) Payables (2009 - 2026)

Abbott Laboratories has disclosed Payables across 18 years of filings, most recently posting $5.8 billion for Q1 2026.

• Payables for Q1 2026 came in at $5.8 billion, up 10.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 billion (up 10.16% YoY), and the FY2025 annual result was $5.3 billion, up 2.26% from the prior year.
• Payables came in at $5.8 billion for Q1 2026 at Abbott Laboratories, up from $5.3 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $5.8 billion in Q1 2026 to a low of $4.8 billion in Q3 2023.
• The 5-year median for Payables is $5.2 billion (2024), against an average of $5.2 billion.
• Across the five-year window, Payables climbed 10.17% in 2022 and declined 9.42% in 2023, its largest moves.
• Abbott Laboratories' Payables stood at $5.5 billion in 2022, then slipped by 4.44% to $5.2 billion in 2023, then dropped by 0.59% to $5.2 billion in 2024, then advanced by 2.26% to $5.3 billion in 2025, then rose by 8.28% to $5.8 billion in 2026.
• The last three Payables figures came in at $5.8 billion (Q1 2026), $5.3 billion (Q4 2025), and $5.2 billion (Q3 2025), per Business Quant data.